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Abstract 
MicroRNAs (miRNAs), an abundant class of ~22-nucleotide non-coding RNAs, regulate the ex-
pression of genes at post transcriptional level. MiRNAs are important regulators of eukaryotic 
gene expression and therefore implicated in a wide range of biological processes. The miR-
NA-related genetic alterations are possibly more implicated human diseases than currently ap-
preciated. Genetic variants in miRNA target sites, called miRNA genes are identified to be asso-
ciated with human diseases. This review discusses about the role of micro-RNA genes in various 
human diseases such as neurodegenerative disorders, cardio-vascular diseases, and metabolic 
disorders, and how they can be targeted as a new therapeutic tool in future with reference to drug 
discoveries/ development. 
Key words: miRNA therapy, novel therapeutics, Neurodegenerative disorders, Cardio-vascular 
diseases and metabolic disorders 
INTRODUCTION 
MicroRNAs (miRNAs or miRs), the post tran-
scriptional regulators constitute a class of small RNAs 
are found in plants, animals, and in a number of DNA 
viruses. Mature microRNAs are a class of about 21–25 
nucleotides in length and small non-coding RNA 
molecules, and occur naturally. They were first de-
scribed in 1993[1], and the term microRNA was cre-
ated in 2001[2]. The main functions of miRNAs are to 
down-regulate the gene expression in translational 
repression, cleavage of messenger RNA (mRNA) and 
in a variety of other processes. Each miRNA is par-
tially or completely accompanied by one or more 
mRNAs. MiRNAs target around 60% of all genes and 
are profusely present in all human cells, and are able 
to repress hundreds of each target. The processed 
mature miRNA molecules are shorter than the final 
mature functional miRNAs. The regulatory elements, 
primary transcripts of miRNAs are shared with their 
respective pre-miRNA, since the residence of them in 
the introns of its specific Pre-miRNA host genes, so 
that they will have similar expression profiles. Few 
primary transcripts have been fully identified for the 
residue of miRNA genes that are transcribed from 
their specific promoters. The transcription processes 
of microRNAs are performed by Pri-miRNAs, and 
RNA precursors that comprise of  cap and poly-A 
tail[3]. Microprocessor complexes processes 
pri-miRNAs which comprises of enzyme RNase III 
Drosha[4]  and the RNA-binding double-stranded 
protein called DGCR8in nucleus[5].An imperfect 
 
Ivyspring  
International Publisher  Theranostics 2013, Vol. 3, Issue 12 
 
http://www.thno.org 
931 
stem-loop structure is formed from the resulted 
pre-miRNAs that are 70-nucleotides in length. 
Ran-GTP and Karyopherin exportin complexes export 
the pre-miRNAs into cytoplasm[6]. The translocation 
of RNA with protein needs ras-related nuclear protein 
(RAN), and a small GTP binding protein that occurs 
through the  nuclear pore complex[7]. The nuclear 
heterotrimer with the pre-miRNAs are formed by the 
binding of Ran GTPase and Exp5 [8]. The double 
stranded miRNA, of 22-nucleotides in length gener-
ated by the processing of pre-miRNA undergoes an 
extra step by the RNAse III enzyme Dicer[9]. The 
formation of the RNA-induced silencing complex 
(RISC) occurs by the Dicer[10]. Due to the miRNA 
expression and RNA interference, the gene silencing 
comes under the responsibility of RISC. Fig. 1 illus-
trates the defects caused by the deletion of ‘Drosha’ or 
‘Dicer’  in anagen, the foremost phase of hair cycle 
during the synthesis of hair in which the active 
product of hair growth occurs in the hair follicle. 
MiRNAs have all types of functions in regulating the 
cell physiology, proliferation, cell differentiation, and 
apoptosis to the endocrine system, hematopoiesis, 
limb morphogenesis and fat metabolism. By reflecting 
the diversity of cellular phenotypes, different expres-
sion profiles are displayed by them from tissue to 
tissue.  
Nomenclature of miRNA 
Since hundreds and thousands of miRNA occur 
in each species, it is important that each new miRNA 
is assigned a specific name, as per the established 
system of miRNA nomenclature. In this system, 
miRNAs that are confirmed by the experiments are 
given a number following the prefix of ‘mir-’. The 
capitalized miR- denotes the mature form of miRNA 
and the un-capitalized mir- refers to the pre-miRNA. 
MiRNAs with similar structures are annotated to 
show their nucleotide structures in number with the 
added lower case letter as miR-1a and miR-1b. As 
miRNAs has the ability to produce the same miRNA 
at different loci, such cases are mentioned with the 
additional numbers and shown as miR-1-1 and 
miR-1-2 [11]. The main annotation in the system of 
nomenclature of miRNA is regarding the Species an-
notation in which the miRNA are observed; for ex-
ample if it is observed in ‘Homosapiens’, it should be 
denoted as, ‘hsa-miR-xxx’. Other miRNAs that are 
commonly seen in the species of viral and Drosophila 
are denoted as v-miRNA and d-miRNA. MiRNAs that 
arises for the 3’ or 5’ end are specified with a suffix of 
-3p or -5p (miR-116-5p, miR- 116-3p). The nomencla-
ture of miRNA can be registered on miRBase.  
 
Figure 1 – (A-H) miRNA depletion, hair shaft defects and permanent hair loss are caused by the deletion of Drosha or Dicer in anagen. (A-D) In-situ 
hybridization for miR-34c in skin. (E-H) In-situ hybridization for miR-205 in skin. (I) After treatment of deoxycycline from P1, this illustrates the qPCR for 
indicated miRNAs using Dicer deleted epidermis. (J-Q) Deoxycycline treatment of Drosha (J-M) and Dicer (N-Q) control and mutant mice. Reproduced with 
permission from Ref. [86].   Theranostics 2013, Vol. 3, Issue 12 
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Cellular functions of miRNAs 
The function of miRNAs is a complementary 
part of one or more mRNAs in gene regulation. By 
causing DNA methylation in promoter sites, the main 
expression of target genes gets affected by miRNAs 
infrequently. MicroRNAs that function as counter-
parts of proteins are collectively called miRNPs. Hu-
man miRNPs contains eIF2C2 (Argonaute 2), DDX20, 
GEMIN4 and MiRNA[12, 13]. 
On the other hand, in as much as functional 
genes are common to all cells, there are only limited 
miRNA target sites, therefore, there are possibilities 
that functional genes may not always be targeted by 
miRNAs  [14]. The microarray dubbed MM-chips 
contains all known miRNA for human, mouse, rat, 
dog and ‘Drosophila’. The class of miRNAs located in 
the introns of the mRNA programming host genes is 
called as Mirtron which plays a bypass role and enter 
as pre-miRNA in miRNA maturation pathway. 
MicroRNAs ROLE IN VARIOUS 
HUMAN DISEASES 
Though ten years got over after the identification 
of first miRNA, only now the scientists have begun to 
comprehend the possibility and diversity of these 
regulatory molecules. Decisive regulatory functions 
exhibited by the miRNA are associated with a wide 
variety of human diseases such as cancer[15, 16] and 
heart disease[17]. MicroRNAs are liberalized in lung, 
breast, and colon cancer, and up-regulated in human 
B-cell lymphomas. MiRNAs are likely to be highly 
applied in future cancer diagnostics, and are attractive 
targets for disease intrusion. In addition to the link 
with cancer, microRNAs play a vital role in the con-
trol of cardiac - related diseases. The integration of the 
ventricular wall, gene expression, contractility, and 
maintenance of cardiac rhythm including myocyte 
growth, can be achieved. For multiple forms of heart 
disease, the mis-expressions of miRNAs were shown 
to be necessary[17].  
This review focuses on the research of miRNA in 
human disease that includes the methodologies for 
gene identification and miRNA targets, and the role of 
miRNA in human diseases. Other than atherosclero-
sis, it mainly focuses on three captions namely, 
•  Neurodegenerative disorders 
•  Cardiovascular diseases 
•  Metabolic disorders 
These details explain on the future role of 
miRNA gene and its therapeutic potential for various 
human diseases through the currently available ap-
plications.  
NEURODEGENERATIVE DISORDERS 
In the neurodegenerative disease, the substantial 
role of miRNA gene in their pathogenesis had been 
documented  [18]. The pathogenic mechanisms in 
psychiatric deficits and neuro-degeneration devel-
opment are not always different, but they are prefer-
ably suited for therapeutic targeting by pleiotropic 
miRNAs. Dicer like miRNA processing machinery, as 
well as the mature miRNA and the precursor subjects 
to the commotion with neurological disease progres-
sion. 
Altered miRNA profiles and the summary of 
derestricted miRNAs have been identified in the 
psychiatric diagnoses like Schizophrenia, autism, 
Fragile X syndrome, depression, addiction, and anxi-
ety[19]. MiRNA derestriction has also been observed 
in peripheral blood, plasma, serum and cerebral spi-
nal fluid (CSF), and furthermore number of studies 
regarding miRNA profiling has been performed for 
neurological diseases[20]. Remarkably, the population 
analyses have been interrupted in some miRNA fam-
ilies that include miR-15 and miR-30 fami-
lies[21].MiRNA disruption has been observed in the 
patients with psychiatric symptoms that co-exist with 
neurodegenerative pathologies such as Parkinson’s 
disease (PD) Alzheimer’s disease (AD) and Hunting-
ton’s disease (HD) [22].In some cases, miRNA inter-
ruption can be seen in both the psychiatric and neu-
rodegenerative diseases. The best example is miR-132 
that has been linked with schizophrenia[23]. Regular 
disruption of miR-132 is seen in wide range of neu-
rological diseases with the principal role of miRNA in 
neuronal plasticity[24]. 
Alzheimer’s disease 
MicroRNAs have recently been involved mostly 
in neurodegenerative disorders including Alz-
heimer’s disease[25]. Alzheimer’s disease brains 
comprise rod-like structures called Hirano bodies[26], 
which consists of actin binding proteins with large 
actions. These proteins are called as Cofilin, which in 
abnormal condition affects the function of cytoskele-
ton[27, 28]. However, the formation mechanism of 
Cofilin-actin is still unknown and this annexation 
plays a dynamic role in pathogenesis of Alzheimer’s 
disease. As the expressions of genes are regulated by 
the large number of miRNA expression in brain, 
miR-107 is decreased in postmortem in Alzheimer’s 
disease human brain. It gets allied with the increased 
expression of Beta-site amyloid cleavage enzyme 1 
(BACE1), where miRNAs plays a major role in the 
pathogenesis of Alzheimer’s disease.  
Also, miR-103 and miR-107 suppress Cofilin 
translation with the increased level of active Cofilin 
protein, which leads in the Cofilin rods formation.  Theranostics 2013, Vol. 3, Issue 12 
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The reduction of miR-103 or miR-107 results in an 
increase in Cofilin protein levels in Alzheimer’s dis-
ease brains[29]. Fig. 2 represents the recognition of 
Cofilin rods in the primary neurons .Most of the 
studies focus on the derivatives of soluble-A and tau 
in Alzheimer’s disease[30, 31], but a few focus on 
blood and CSF and have reconnoitered the role of 
miRNA[32, 33]. It will be really interesting to cartel 
with circulating miRNAs in the future researches and 
even most of the studies discussed about the miRNA 
in Alzheimer’s disease; there is no conclusive evi-
dence for the miRNA target gene regulation in-vivo. 
These are addressed to gain an advanced knowledge 
of the contribution of miRNAs in Alzheimer’s disease. 
As mice are genetically homogenous comparing to 
humans, it’s quite easy to study miRNA related gene 
pathways in the Alzheimer’s disease development. 
Due to the indications of profiling studies in human, 
that Alzheimer’s disease brain gets altered by the 
miRNA gene expression, and it is to be patterned 
whether the changes are specific to this particular 
disease or it tends to overall reduction of miRNA 
function remains to be detected. MiRNA gene 
knockout is required to address these and other en-
thralling suggestions. 
 
Figure 2 – Cofilin rods in the primary neurons (top) are recognized by an 
antibody to total actins (bottom). The scale bar representation is 100 µm. 
Reproduced with from Ref. [29]. 
Parkinson’s disease 
MiRNAs are accompanying with the pathogen-
esis of Parkinson's disease, as found in many other 
diseases[34, 35]. Nowadays, many unfathomable 
perceptions into neuro-pathogenesis in Parkinson’s 
disease have been studied in more number; however 
this review describes about a few increasingly studied 
miRNA that deals with the Parkinson’s disease, which 
is generally associated with Aging and hence has a 
high incidence in elderly individuals. The obliteration 
of dopaminergic neurons in the mid-brain or the in-
sertions of proteins and Lewy bodies results in Par-
kinson’s disease. The inspection of molecular pro-
cesses in normal control and human diseases can be 
obtained by a novel approach of the study of miRNA.  
N-Myc down-regulated gene 1 (NDRG1) and 
junction plakoglobin (JUP) are the two new transcrip-
tional factors noted in eleven genes, which are identi-
fied by miRNA and the transcription factors associ-
ated with Parkinson’s disease, in which the regulation 
of NDRG1 is achieved by miRNA-133[36]. MiR-7, 
miR-153 and miR-433 modify the expression of 
α-synuclein in Parkinson’s disease as shown in Fig. 3. 
The decreased expression of miR-34b and miR-34c 
was indicated by the miRNA profile analysis and the 
changes were found in the frontal cortex, cerebellum, 
and amygdala in Area 17 of brain. The depletion of 
miR-34b or miR34c results in the decreased expression 
of Parkinson protein 2 (Park2) and Parkinson protein 
7 (DJ1) and Cell death. Mitochondrial dysfunction is 
finally resulted by these kinds of cellular changes in 
Parkinson’s disease[35].As the studies of miRNA mi-
croarrays results about 4% of miRNAs were from 
healthy brain tissues, it should be checked also in the 
plasma of healthy controls. For the process of Valida-
tion and Evaluation of the biomarkers from the new 
set of replication in Parkinson’s disease and controls, 
the quantitative real-time Polymerase Chain Reaction 
technique (qRT-PCR) can be done. To lower the bi-
omarker performance, the biomarkers at the high 
predictive performance can be combined and applied 
to a new panel of independent set of validation.  
For the future research, most of the detailed par-
ticipation of miRNA should be studied in the field of 
Neuro-degeneration. Here are some suggestions that 
may virtue some reflection in the future research of 
miRNAs in Neurodegeneration: 
•  With convoluted functions and requirement of 
protein translation long, neurons are differenti-
ated in a geometrical manner by their respective 
asymmetric shape. It takes many centimeters in 
some places from the cell nucleus. It should be 
noted for the perturbation of the translational 
control contributed to Neurodegeneration, if 
miRNA plays a vital role in localized control of  Theranostics 2013, Vol. 3, Issue 12 
 
http://www.thno.org 
934 
messenger RNA (mRNA). 
•  Due to the alterations of miRNA related to 
Neurodegeneration, alteration of biochemical 
function should be checked, whether the miRNA 
alteration occurs because of the alteration in 
RNAs in Neurodegeneration.  
•  The miRNAs related pathways like Apoptosis, 
cell division, etc., relevant to earlier development 
may be pathogenic in the adult brain.  
•  It should be checked whether the Risk factors of 
Neurodegeneration affects the miRNA brain 
expression and miRNA-related biochemical 
predictions for therapeutics. 
Schizophrenia 
Schizophrenia is a devastating complex neuro-
psychiatric disorder categorized by cognitive im-
pairments that involves interruptions in neural cir-
cuitry and synaptic function. The neural network ne-
cessitates coordination by an intricate intracellular 
network of molecular signal transduction systems. 
The potential of combinational gene variants cause 
system dysfunction as related to neurobehavioral 
syndromes that are meant by the neural networks 
termination. MicroRNAs are mainly used for the to-
pography shaping of these networks, which have a 
potential for the regulation of target genes by the 
function of miRNA in Intracellular gene-silencing 
machinery as their specificity factor. Later in the 
mammalian brain, miRNA displays composite tem-
porospatial expression patterns. During development 
ubiquitous changes occurs in the network due to the 
dysregualtion of miRNA which also happens in the 
matured brain. This is highly significant in the path-
ophysiology of Schizophrenia and can be the regula-
tory factor in most of the human genes in the tis-
sue-specific stages of development [37, 38]. 
A surfeit of postmortem studies using cases 
spotted with Schizophrenia delivered a solid support 
for deviant expressions of miRNA in psychiatric dis-
orders [39-41]. miR-132 and miR-212 are involved in 
several abnormalities like synaptic plasticity and 
connectivity in Schizophrenia and in neuronal cul-
tures, the mature miR-132 stability is affected by 
NMDA inhibition[42]. Similarly, the pharmacological 
blockage in NMDA receptors leads to the 
down-regulated expression of miR-219[43]. Other 
important miRNAs that play a major role in Schizo-
phrenia are miR-195, which regulate more number of 
Schizophrenia-related genes[44] and miR-137 the ex-
pression of which gets inhibited by Mecp2 that targets 
other chromatin modifying genes.  
Epilepsy 
Epilepsy is a chronic neurological disorder that 
forms unprovoked seizures; in some cases, it forms a 
single seizure combined with brain alterations that 
later forms more number of seizures in brain. MiR-
NAs takes their roles in the pathogenesis of sei-
zure-induced epilepsy and the change of multiple 
miRNAs expression are detected by miRNA profiling, 
which in late follows miRNA regulation in human 
epilepsy  [45, 46]. The novel targets for neu-
ro-protection and anti-epileptogenesis can be attained 
by the identification of miRNAs regulating sei-
zure-induced neuronal death [47, 48]. MiR-34a ex-
plored its role as up-regulation due to its presence in 
p-53 dependent control of apoptosis[49]. Several other 
miRNAs like miR-21, miR-29a and miR-132, were 
identified as p53 regulated and also they gets regu-
lated after seizures formation. Future studies in 
miR-34a can help to achieve the cure for Epilepsy, as it 
only has the ability to control by medication. 
 
 
Figure 3: The regulatory network of miRNAs in parkinson’s disease showing the expression of α-synuclein and its modification by specific miRNAs like 
miR-7, miR-153 and miR-433. Reproduced with permission from Ref.[87].  
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Down syndrome 
Down’s syndrome disease, also called trisomy 
21, is a chromosomal genetic disorder caused by the 
presence of the third copy of Chromosome 21 and it is 
more common in human that leads to intellectual 
disability. Down’s syndrome is associated with men-
tal retardation and delay in physical growth. The 
rapid proliferation of astrocytes called Astrogliosis, is 
associated with the Down’s syndrome. In the brain 
tissues of Down’s syndrome and Astrogliosis induced 
human astrocytes, the levels of miR-125b gets 
up-regulated in its enrichment. This kind of miRNA 
can be studied in future for their contribution in 
Neurodegenerative disorders, as miR-125b has mul-
tiple targets in the brain affected with Neurodegener-
ative disorders [50, 51]. 
CARDIOVASCULAR DISEASES 
The growth, survival, function and gene expres-
sion of Cardiomyocyte gets regulated by the disrup-
tion in normal mechanisms, intricate in the patho-
genesis of heart failure. The heat map diagram for the 
illustration of circulating miRNA profile in Coronary 
Artery Disease (CAD) patients and healthy volunteers 
has been compared [50]. Cardiac Fibrosis and Myo-
cardial Infarction results with the participation of 
Cardio-vascular cells and Cardiac-interstitial cells, but 
some novel therapeutic targets by miRNA have 
proven to be clinically applicable and that is described 
in the following, as disease segmented.  
Myocardial Infarction  
MiR-21 is an Oncomir, since it exerts oncogenic 
activity and it is the only miRNA  that got gradual 
up-regulation in both cancer and cardio-vascular 
diseases like Myocardial Infarction. This particular 
miRNA contributes to the progression of fibrosis and 
heart failure or block and highly seen in the fibro-
blasts, in the cardiovascular system. Against heart 
diseases like infarction, miR-21 serves as a major part 
in the development of therapeutic strategies. The in-
hibition of this specific miRNA (miR-21) by the syn-
thetic miRNA antagonist results in the improvement 
of heart function in cardiac disease model. The same 
constructive effects were observed in miR-21 knock-
out mice exposed to pressure-overload of the left 
ventricle emphasizing the key role of miR-21 as a 
therapeutic target. Comparing to the healthy controls, 
coronary artery disease patients undergo a reduction 
of miR-145, miR-17, inflammation-accompanying 
miR155 which reduces the circulating levels of angi-
ogenesis-related miR-126 and miR-92a;Coronary ar-
tery disease patients shown an elevation in the 
miR-133a and miR-208a levels of cardiac muscle en-
richment.  
Of the genome, 50% is allotted for the miRNA to 
function as regulators and that’s the main reason for 
probable use of miRNA as novel therapeutic targets to 
modulate cardiovascular signal transduction. After 
the cardiac stress, the  signal transduction may be 
helpful for the cardiac regeneration. Mammalian 
miRNAs show a partial complement to respective 
mRNAs due to the small interference RNA mediated 
gene silencing. Also the mammalian miRNAs possess 
stronger biological effects which facilitate their use as 
multiple targets. Cardiac remodeling and the devel-
opment of heart failure are attained by Myocardial 
infarction (MI); the perilous event is, after the Myo-
cardial Infarction, it is noted that the myocardial ca-
pillary density is not sufficient. However, the Cardiac 
mechanisms are not well understood. To regenerate 
Endothelial cells after Myocardial Infarction, a new 
miRNA has been identified which increases cardiac 
function and decreases the infarct size [37]. To regen-
erate cardiac tissue after the Myocardial Infarction, 
Stem cell based transplantation ideas are currently 
hindered within the affected area and inflated fibrosis 
by the ischemic environment. These processes can be 
targeted now by miRNAs and as the miRNA ap-
proaches got into  clinical phase studies in a short 
time, thus indicating the high translational impact of 
miRNA therapeutics in future, but it remains as a 
great challenge to interpret such tactics into a thera-
peutic cardiovascular locale. 
Cardiac fibrosis 
Another important cardio-vascular disease with 
high incidence is myocardial fibrosis, which is a vital 
complication of most forms of human heart disease. 
By regulating cardiomyocyte apoptosis and discharge 
of pro-fibrotic factors, myocardial fibrosis gets influ-
enced by myocyte-specific miRNAs. It also gets reg-
ulated by miRNAs that are expressed in Cardiac fi-
broblasts[38]. Some of the major examples that play a 
high role in this process is two miRNAs, miR-21 and 
miR-29, which are extensively expressed as miRNAs 
that are highly augmented in apparently cardiac fi-
broblasts compared to myocytes [39, 40].  In an ex-
perimental heart failure model, up-regulation of 
miR-21 was narrowed to cardiac interstitial cells and it 
shown to promote cardiac fibrosis[39]. 
Down-regulation of miR-29 in limit zone myocardium 
has been associated with the contribution in myocar-
dial fibrosis[40]. Predicted miR-29 targets encom-
passed fibrosis-related mRNAs that include collagens 
with increased expression in heart of miR-29b an-
tagomir knockdown mice. This overexpression of 
miR-29b in cultured cardiac fibroblasts contracted 
collagen expression[38]. 
Cardiomyocyte are reliant on an opulent vascu- Theranostics 2013, Vol. 3, Issue 12 
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lar complex, maintenance of which is dependent upon 
complex signaling between cardiac interstitial, car-
diomyocyte,  and endothelial cells. Vascular homeo-
stasis is determined by the proangiogenic and anti-
angiogenic signaling balance. miR-126 is the only 
endothelial-specific miRNA that regulates angiogen-
esis[41, 42]. Isolated non-myocytes from the hyper-
trophied myocardium  of calcineurinin transgenic 
mice, miR-126 was also down-regulated[43]. MiR-23a 
was up-regulated by the activation of calci-
um-dependent pathway which acts as a vital facilita-
tor of cardiac hypertrophy, called Calcineurin-NFAT 
pathway[44]. Calcineurin –NFAT pathway block was 
attained by antagomir-mediated loss of miR-23a ac-
tivity[44]  and the overexpression of miR-23a drives 
cardiomyocyte hypertrophy[45]. MiR-24, miR-195 and 
miR-214 are other significant miRNAs that regulates 
cardiac hypertrophy[45]. In Smooth muscle cells, 
miR-143 and miR-145 are co-transcribed miRNAs that 
get expressed, which were down-regulated in ather-
osclerotic vessels for the promotion of differentiation 
and for the process of inhibiting proliferation[46]. 
Atherosclerosis 
Hemodynamic forces like hydrostatic and fluid 
shear stress, plays a major role in the development of 
physiology and vessel maturation. They are subjected 
with the blood vessels and the monolayer that is in 
straight contact with flowing blood, vascular endo-
thelial cells are continuously exposed to blood 
flow-induced shear stress. Atherosclerosis occurs 
normally in arterial curvatures and branches that 
have very low and dynamic shear stress[47]. The 
dysfunction of endothelial cells is the preliminary step 
of Atherosclerosis  and an inflammatory response 
through peroxisome proliferators-activated recep-
tor-α by 3'-UTR targeting achieved as a result of in-
duced expression of miR-21 in cultured endothelial 
cells at the transcriptional level, due to the Oscillatory 
Shear Stress (OSS)[48]. In endothelial cells, the ex-
pression of miR-92a is down-regulated by the Pulsa-
tile Shear Stress (PSS), whereas the same gets 
up-regulated by Oscillatory Shear Stress 
down-regulated. KLF-2 gene serves as a target for 
miR-92a, which get up-regulated by athero-protective 
shear flow like Pulsatile Shear Stress and Laminar 
Shear stress, whereas it gets down-regulated by Os-
cillatory shear stress stimulated endothelial cells and 
it is confirmed by the demonstration of bioinformatics 
analysis. Thrombomodulin (TM) and eNOS are the 
regulated genes of KLF-2, which were repressed in the 
endothelial cells by the overexpression of miR92a. So, 
the regulatory responses of KLF-2 and miRNAs to-
wards athero-protective shear flow can be predicted 
by a new concept. Another miRNA is also shown to 
be regulated by shear stress;, MiR-663[49] plays a vital 
role in the modulation of inflammation and prolifera-
tion of endothelial cells. 
By various cultured cells and animal models, the 
involvement of several miRNAs in the biological 
progressions have been identified and that aid to 
study the expression profiles of circulating 
miRNAs[50] in Cardiovascular disease patients. The 
Peripheral blood mononuclear cells (PBMCs)[51] that 
underlies with the involvement of miRNAs; unfortu-
nately, the involvement of miRNAs in atherosclerotic 
plaques has not received fine consideration. In the 
human atherosclerotic plaques from peripheral arter-
ies, the expression profiles of miRNA were investi-
gated in comparison to the non-atherosclerotic Left 
internal thoracic arteries (LITA)[52]. Also the rela-
tionship between the miRNA expression profiles and 
biological processes in atherosclerosis was elucidated. 
It is found that miR-21, -34a, -146a, -146b-5p, and −210 
were expressed at substantial levels and in human 
atherosclerotic plaques and these mentioned miR-
NA’s frequent prophesied targets were 
down-regulated. MiR-34a was recognized as a novel 
therapeutic target for the pathogenesis of atheroscle-
rosis, mainly because of its function in apoptosis.  
MiR-146a family (miR-1461/b) is highly ex-
pressed in atherosclerotic plaques and gets regulated 
downstream through a negative-feedback regulation 
loop. By utilizing the Lipopolysaccharide – stimulated 
human monocytic cell line that an elevated miR-146 
expression has been noted[53]. The contribution of the 
activity of endothelial cells to the lower levels of cir-
culating miRNAs may be required, since the perfect 
mechanisms of reduction of circulating miRNAs is 
uncertain. In blood, by leading to the reduction of 
circulating miRNAs, as another insinuation, circulat-
ing miRNAs are taken up into atherosclerotic lesions. 
METABOLIC DISORDERS 
Biological functions of microRNA is much less, 
though hundreds of miRNA were identified. In 
greater organisms, miRNAs affect the fundamental 
pathways for the metabolic control such as adipocyte 
and skeletal muscle differentiation. It is a completely 
requisite for all living cells to make changes in the 
internal or external environment in response for the 
ability to control the rates of metabolic processes. 
Transcriptional, translational, posttranslational and 
allosteric regulations are the Complex mechanisms 
that are highly involved in the metabolic control and 
the maintenance of homeostasis. To add an innovative 
level of regulation and fine-tuning for gene expres-
sions, miRNA aids a foremost part by comprising the 
novel class of genes that is significant for a wide sort 
of metabolism. The possibilities of miRNAs to con- Theranostics 2013, Vol. 3, Issue 12 
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tribute themselves on metabolic disorders highly 
points on more common human metabolic control like 
diabetes and obesity, which are detailed below to 
list-out the novel therapeutic chances by targeting 
miRNAs 
Diabetes mellitus 
Pancreatic  β-cells play a vital role in diabetes 
mellitus and in the complex mechanism of glucose 
homeostasis by involving in the Insulin production. In 
the development and maintenance of the pancreatic 
islets, miRNAs commences to involve in the insulin 
pathway. The flaw in the production of insulin and in 
β-cells with an imperfection of the endocrine pancre-
atic lineage development was attained by the ablation 
of Dicer 1 which causes miRNA processing block[54]. 
In diabetic controls, both the mRNA and protein lev-
els were decreased by the Dicer-1-deificient  β-cells 
and the levels of transcriptional repressors, Bhlhe22 
and Sox6, were increased by silencing miR-24, miR-26, 
miR-148 or miR-182 in autonomous[55]. This leads to 
the down-regulation of mRNA levels and specific 
insulin promoter activity, by affecting the insulin 
transcription levels which assures that miRNAs 
therapeutic targets in Diabetes mellitus whereby 
modulation in their expression regulates insulin 
production. 
MiR-375 is the most studied miRNA that are ex-
pressed in the pancreas and are overexpressed in the 
islet cells. These miR-375 functions on the control over 
glucose-stimulated insulin release and the overex-
pression of miR-375 inhibits insulin secretion[56]. 
Reduced β-cell mass and increased a-cell number was 
seen in miR-375 knockout mice that exhibited the di-
abetic phenotypes like hyperglycemia and glucose 
intolerance  [57]. A section of ten miRNAs such as 
miR-27a, miR-130a, miR-192, miR-200a, miR-320, 
miR-337, miR-369-5p, miR-379, miR-410 and miR-532, 
were down-regulated in the concluding group[58]. 
Reduced glucose-stimulated insulin secretion was 
obtained by the knockdown of miR-410, miR-200a and 
miR-130a separately and a significant reduction in the 
expression with glucose treatment was confirmed by 
miR-690, miR-484 and miR-296 and the up-regulation 
of miR-124a, miR-107 and miR-30d. Thus the com-
plete interaction network of miRNAs in Type-2 Dia-
betes mellitus is shown in Fig. 4 and collectively these 
studies discovered the network of miRNAs for the 
maintenance of insulin synthesis and secretion by 
controlling the range of mRNAs and miRNAs poten-
tially contribute to the manifestation of diabetes. 
Obesity 
Obesity is categorized with diminished adipo-
cyte function and aberrations in adipokine secretion 
that are associated with insulin resistance. The lean 
individuals with more peripheral distribution of fat 
are more insulin sensitive than the obese individuals 
who have their fat distributed in the central abdomen. 
miRNA profiling of human fat cells recognized an 
increase in the expression of miR-100, miR-125b, 
miR-221 and miR-34a and the down-regulation of 
miR-130b, miR-185 and miR-210 in obese subjects[59]. 
During adipocyte differentiation and maturation, 
miR-100, miR-125b, miR-221 gets down-regulated, 
whereas miR-130b and miR-210 decreased in their 
expression[60], but miR-143 showed a positive asso-
ciation  with bodyweight and mesenteric fat 
weight[60]. Important correlation between the mor-
phology of adipose tissue and the expression levels of 
miR-17-5p, miR-132, miR-134, miR-145, miR-181a, 
miR-197 and miR-99a were reported with the fasting 
plasma glucose and  circulating leptin, adiponectin 
and IL-6[61]. Significant differences between obese 
and non-obese fat were reported by the expression 
levels of miR-17-5p and miR-132[62]. Thus these 
studies provide the insinuations of the miRNA in 
obesity. 
As the wide medical vocation is very alarmed by 
the growing incidence of overweight and obesity and 
its main association with the increased health risks, 
miRNA researches will be more helpful in its specific 
clinical applications and they can be pointed-out by 
focusing the future perspective miRNA researches in 
them. Also, this can be attained by revealing studies 
regarding the expression criteria.  
 
Figure 4: The interaction network of miRNAs in Type – 2 Diabetes 
mellitus with the triangular regions representing the miRNAs that nega-
tively regulate the refined genes and the round regions representing the 
genes of the refined gene set. Adopted from Ref. [88].  
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Methodologies used in Gene Identification 
Various successful methods and techniques to 
identify the computational part of the gene, is a major 
thrust research area. Due to many imperative func-
tions of these tiny gene regulators, like patterning of 
nervous system[63], miRNA genes are planned to be 
identified, which develops miRscan and conserved in 
more than one genome. The conserved intronic and 
intragenic regions in D. melanogaster and D. pseudoob-
scuraare followed by additional algorithm[64]. The 
development of that algorithm can be achieved by the 
conversation of those short sequences. Based on the 
sequence conservation between Arabidop-
sis and Oryzagenome, a wide computational approach 
got developed[65], to detect miRNA genes present in 
the  Arabidopsis genome. An additional approach is 
based on stiff complementarities between miRNAs 
and their targets, for the detection of miRNAs in A. 
thaliana. 
The factors for the development of algorithm 
other than the Conservation of sequence were also 
described. Bentwitch  combined Sequence directed 
cloning and microarray analysis with bioinformatics 
prediction in the year 2005, which was an integrative 
approach[66]. The distant/close homolog identifica-
tion can be attained by the probabilistic co-learning 
method that got developed by the information at se-
quence and structural level[67]. Wang and his 
group were able to develop a novel computational 
approach with miRAlign for the detection of new 
miRNA based on structure and sequence 
alignment[68]. For the identification of candidate 
miRNA homolog in a set of sequences, the developed 
Micro-Harvester by similar sequence and structure 
information can be used and additional concept, that 
miRNAs are repeatedly found in groups, was the ba-
sis of mirAbela[69] that took into consideration only 
those genomic regions that are present around known 
miRNAs from mouse, rat and human. 
As new theories were formed by the Novel con-
cepts, Berezikov[70] reported a characteristic conser-
vation profile used for the detection of known miR-
NAs efficiently, which was revealed by the phyloge-
netic shadowing of miRNAs in primate species. It 
predicts a wide-ranging set of miRNAs based on hu-
man- mouse-rat genome wide comparisons. 
Most of the predictor algorithms depend on 
miRNA sequence conversations among diverse spe-
cies. Such approaches are obviously limited to de-
tecting only the conserved microRNAs. For the iden-
tification of non-conserving miRNAs, the machine 
learning concept entered, which has a difficult pat-
tern-recognition challenging. For unique true 
pre-miRNAs from other pre-miRNA like hairpin 
structures taking into account a novel local connecting 
structure sequence feature, and developed a first 
method[71]  called as Triplet-SVM, and used SVM 
with these structures to classify real and pseudo 
pre-miRNAs.  To improve the calculations by Tri-
plet-SVM, additional tool MiPred was developed in a 
combined way with other features with the MFE of 
the secondary structure[72]. 
Potential miRNA targets 
The product of the genes that miRNA regulates 
can be alleged by the specific miRNA’s function. The 
information regarding the genomic targets of miRNA 
is also included in the miRBase with the miRNA se-
quence data, from the miRNA gene identification 
shifted up to the functional characterization. For the 
extrapolation of miRNA targets in mRNA sequences, 
there are number of computational techniques exist-
ed, even though it is very difficult to detect the targets 
for the large-scale experiments [73-78]. Both for the 
selection of targets for experimental validation and for 
the prediction of potential targets, the existed meth-
ods can be used but for the most part, with a large 
degree of miRNA complement, the potential binding 
sites of miRNA are detected as the first step by the 
computational techniques. This is then followed by 
filtering out of the sites that do not appear to be un-
spoiled in various numbers of species. However, the 
species that not possess closely related genome se-
quences has deprived protection measure, regarding 
the species having orthologs clearly defined and 
closely related species like human, mouse and rat, this 
approach appears to work well for them specifically. 
MicroRNAs APPLICATIONS  
The upcoming paragraphs will describe about 
the applications of MicroRNAs and its complete role 
as Composite biological links, unintentional cancer 
genes at Genomic divisions, tumor suppressing po-
tential and in tumor invasion metastasis. The overall 
expressions of various miRNAs that are discussed in 
this review are figured out in Fig. 5. The future role of 
MicroRNAs details about the suggestions and 
measures that can be taken in the research of various 
human diseases like Alzheimer’s disease (AD), Par-
kinson’s disease (PD) and Cardio-vascular diseases 
like Myocardial Infarction.  
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Figure 5: A cartoon showing the major miRNAs described in this review with their target specific functions and related human diseases. 
 
 
Composite biological links 
The expressions of miRNA may differ on com-
paring the metastatic lesions with the malignancies 
harbor distinct patterns, which have been studied in 
more number and consisted of keen profiling for the 
investigation of global patterns of miRNA expression 
in malignancies. But, to have an essential role in 
Cancer biology, the appearance of selected miRNAs 
occurs [79, 80]. By understanding the roles of miRNAs 
in transcriptome and proteomic levels, helps to shape 
the modulation of the multiple biological links, as all 
the miRNAs don’t undergo an isolated function. More 
than 4000 human cancers were evaluated for the 
miRNA expression with an example of hiring miRNA 
in an example of placing miRNAs in the perspective 
of pathways. For example, multiple numbers of 
MiRNAs inclines to be up-regulated namely, miR-21, 
miR-17, and miR-92a, whereas miR-205 and miR-145 
like miRNAs tends to be down-regulated [81] in sev-
eral kinds of cancers. In addition, bunches of select 
miRNAs inclined to differentiate subtypes of cancers. 
This assures that the multiple miRNAs are more ac-
tive than the single miRNA function in Cancer. The 
subtypes of cancers are differentiated by the cluster of 
miRNAs and by assimilating the data of genome 
helps for the identification of the factual signal, so that 
that can be even more perplexing. Using mathemati-
cal calculations, Zhang group[82]  analyzed the ex-
pression of mRNA and miRNA by multiple number 
of ovarian cancer samples which underwent DNA 
methylation and identified about the mul-
ti-dimensional modules. 
Genomic divisions as unintentional Cancer 
genes 
An involvement of miRNAs in cancer was ex-
plained as the first indication in the field of miRNA’s  Theranostics 2013, Vol. 3, Issue 12 
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applications in Cancer[83] and the deletion of abnor-
mal chromosome 13 in Chronic lymphocytic leukemia 
(CLL) contribute to leukemogenesis. Calin group 
identified miR-15 and miR-16 in the deletion part of 
the chromosome as an unintentional gene and their 
expression in CLL patient’s blood samples were ana-
lyzed with the result of absence of both the miRNAs 
when compared to normal lymphocytes. This con-
firms that miR-15 and miR-16 are involved in the CLL 
pathogenesis. Three major breakthroughs have been 
pointed out in the year 2005, firstly, the contribution 
of miRNAs to carcinogenesis and secondly, about the 
relationship between miR-17-92 and the Myc onco-
genic pathway[84]. 
Metastasis and tumor incursion 
In cancer, miRNA expression may be driven by 
the transcriptional links as reported by Ma and 
group[85]  with the suppression of the direct target 
and activation of pro-metastatic gene by the induction 
of specific miRNA expression due to the pleiotropic 
transcription factor twist and leads to tumor cell in-
cursion and metastasis. This pleiotropic transcrip-
tional factor twist induces the expression of miR-10b 
which promotes cell migration and invades in breast 
cancer cells, which gets correlated with clinical pro-
gression. These findings of Ma group suggest that 
specific miRNAs have a role on the event of tumor 
initiation by contributing directly in tumor incursion 
and metastasis. 
 
Table 1: List of MicroRNAs and their corresponding functions in various human diseases 
MicroRNAs  Disease  Function  Reference 
miR-132  Neurodegenerative and Psychiatric disorder  Helps in Neuronal plasticity for both of the disor-
ders 
[21] 
miR-103 
miR-107 
Neurodegenerative disorder – Alzheimer’s dis-
ease 
Repress Cofilin translation  [28] 
miR-133  Neurodegenerative disorder – Parkinson’s dis-
ease 
Regulation of NDRG1  [35] 
miR-34b 
miR-34c 
Neurodegenerative disorder – Parkinson’s dis-
ease 
Decrease Park2 and DJ1 expression with Cell Death [34] 
miR-132 
miR-212 
Neurodegenerative disorder – Schizophrenia  Causes abnormalities in synaptic plasticity   [41] 
miR-219  Neurodegenerative disorder – Schizophrenia  Blocks NMDA receptors  [42] 
miR-195  Neurodegenerative disorder – Schizophrenia  Regulates more no. of Schizophrenia related genes  [43] 
miR-34a  Neurodegenerative disorder – Epilepsy  Apoptosis control   [48] 
miR-125b  Neurodegenerative disorder – Down’s syn-
drome 
Has multiple targets in the diseased brain  [49, 50] 
miR-17, 21, 92a, 126, 
133a, 145, 155, 208a  
Cardio-vascular disease – Myocardial Infarction  Develops therapeutic strategies   [51, 52] 
miR-29b  Cardio-vascular disease – Cardiac fibrosis  Contracts Collagen expression  [52] 
miR-126  Cardio-vascular disease – Cardiac fibrosis  Regulates Angiogenesis  [55, 56] 
miR-23a  Cardio-vascular disease – Cardiac fibrosis  Blocks calcineurin-NFAT pathway   [58] 
miR-24, 195, 214  Cardio-vascular disease – Cardiac fibrosis  Regulates Cardiac hypertrophy  [59] 
miR-663  Cardio-vascular disease – Atherosclerosis  Modulates inflammation and proliferation of En-
dothelial cells 
[63] 
miR-21, 34a, 146a, 
146b-5p, 210 
Cardio-vascular disease – Atherosclerosis  Expressed at substantial levels and in Atheroscle-
rosis plaques 
[64] 
miR-146a, 146b  Cardio-vascular disease – Atherosclerosis  Expressed in Atherosclerosis plaques  [67] 
miR-24, 26, 148, 182  Metabolic disorder – Diabetes mellitus  Increases the levels of transcriptional repressors  [69] 
miR-375  Metabolic disorder – Diabetes mellitus  Controls the release of over glucose stimulated 
Insulin 
[70] 
miR-27a, 130a, 192, 200a, 
320, 337, 369-5p, 379, 410, 
532 
Metabolic disorder – Diabetes mellitus  Gets down-regulated in the concluding group  [72] 
miR-100, 125b, 221, 34a, 
130b, 185, 210 
Metabolic disorder – Obesity  Increases miRNA profiling of human fat cells   [73] 
miR-143  Metabolic disorder – Obesity  Positively associated with body weight and mes-
enteric fat weight 
[74] 
miR-17-5p, 99a, 132, 134, 
145, 181a, 197 
Metabolic disorder – Obesity  Alters the morphology of adipose tissue  [75] 
miR-17-5p, 132  Metabolic disorder – Obesity  Differentiates obese and non-obese omental fat  [76] 
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CONCLUSION 
In this review, we have addressed in detail the 
contribution of miRNA genes in earlier studies with 
the future perceptions, the methodologies for gene 
identification and the applications of miRNA genes 
and their therapeutic potential for the human diseases 
like neuropsychiatric and neurodegenerative disor-
ders, cardio-vascular diseases and metabolic disor-
ders. In conclusion miRNAs are critical regulators in 
human diseases, holding the promise of being a new 
class of therapeutic targets for current drug discovery 
and developmental biotechnology applications. 
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